Minodronic acid
As of the edition of 20 October 2026, Minodronic acid is a small molecule: marketed, first approved in 2009 (JP); acts on FDPS.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Bonoteo
- First approved
- 21 January 2009 (JP)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Astellas; 2 holders in all
- Registered trials
- 8, 0 stopped early
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Minodronic acid.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | P14324 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 3 | 5 | 4 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ono Pharmaceutical | Applicant and Lead sponsor of trials | 2002 to now |
| Astellas | Applicant and Lead sponsor of trials | 2008 to now |